medigraphic.com

2019, Number 4

<< Back Next >>

Rev Hematol Mex 2019; 20 (4)

Epidemiological characteristics at time of diagnosis of three hematological neoplasms of lymphoid origin in a domestic reference hospital

Nambo-Lucio MJ, Natividad Muñoz N, Cleto-Gutiérrez SA, Regalado-Ramos JA, Herrera-Rojas MÁ

Language: English
References: 26
Page: 262-272
PDF size: 265.26 Kb.


ABSTRACT

Objective: To identify the demographic, clinical characteristics and the most frequently prescribed treatments of patients with diagnosis of non-Hodgkin mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) who received care at a Mexican hospital.
Material and Method: A retrospective study was conducted, analyzing the clinical records of patients with diagnosis of MCL, CLL, or MM who received care at the Siglo XXI National Medical Center Cancer Hospital Hematology Service from June 2008 to October 2016.
Results: 399 patients were included, 214 (54%) men, with median age of 60 years (38 to 88). The distribution was 31 (8%) patients with MCL, 21 (5%) with CLL, and 347 (87%) with MM. The most common initial clinical manifestation was weight loss in MCL and CLL, and lumbar pain in MM. The median time for a patient to see a doctor was greater in patients with MM than in MCL and CLL (7.2 vs 5 and 6 months). The common denominator in the three neoplasms was that most of patients were in an advanced stage of the disease at the time of diagnosis.
Conclusion: Most of demographic characteristics of patients included were similar to those described in the literature; however, the age of patients with myeloma was lower, the time to diagnosis was greater and stage of disease at diagnosis was higher than expected.


REFERENCES

  1. Tirado-Gómez LL, Mohar A. Epidemiología de las neoplasias hemato-oncológicas. Inst Nac Cancerol 2007;2:109-20.

  2. Secretaría de Salud, Dirección General de Epidemiología. Registro histopatológico de neoplasias malignas. Compendio: mortalidad y morbilidad. 2000.

  3. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Incidence and survival in sarcoma in the United States: A focus on musculoskeletal lesions. Anticancer Res 2013;33(6):2597-604.

  4. Rizo P, Sierra MI, Vázquez G, Cano M, Meneses A, Mohar A. Registro Hospitalario de Cáncer: Compendio de Cáncer 2000-2004. Inst Nac Cancerol 2007;2(2):203-87.

  5. Labardini JR, Cervera E, Corrales C, Balbuena M, Barbosa A, Espinoza J, et al. Oncoguía. Linfoma no Hodgkin. Inst Nac Cancerol 2011;6:139-52.

  6. Globocan 2008 [Internet]. Available from: http://wwwdep. iarc.fr

  7. Cano R, Alvarado M, Álvarez E, Baltazar S, Castellanos E, Castillo MH, et al. Primer consenso en leucemia linfocítica crónica de la Agrupación Mexicana para el Estudio de la Hematología: epidemiología, diagnóstico y tratamiento. Med Univ 2008;10(40):159-67.

  8. Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Wierda WG, Gribben J, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Prim 2017;3(Cll):16096. doi: 10.1038/nrdp.2016.96.

  9. Hernandez-Caballero A, Arellano-Llamas AA, Cruz-Rico J, Ojeda JV, Tuna-Aguilar E, Aguayo-Gonzalez A, et al. Genetic susceptibility variants for chronic lymphocytic leukaemia in Mexican mestizos. Br J Haematol 2015;169(6):909-11. doi: 10.1111/bjh.13259.

  10. Curado MP, Oliveira M, Silva D, Souza D. Epidemiology of multiple myeloma in 17 Latin American countries: an update. Cancer Med 2018;7(5):2101-8. doi: 10.1002/ cam4.1347.

  11. Hari P. Recent advances in understanding multiple myeloma. Hematol Oncol Stem Cell Ther 2017;10(4):267-71. doi: 10.1016/j.hemonc.2017.05.005.

  12. Gordon LI, Bernstein SH, Jares P, Kahl BS, Witzig TE, Dreyling M. Recent advances in mantle cell lymphoma: Report of the 2013 Mantle Cell Lymphoma Consortium Workshop. Leuk Lymphoma 2014;55(10):2262-70. doi: 10.3109/10428194.2013.876634.

  13. Wang Y, Ma S. Racial differences in mantle cell lymphoma in the United States. BMC Cancer 2014;14:1-8. doi: 10.1186/1471-2407-14-764.

  14. Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011;21(5):293-8. doi: 10.1016/j.semcancer.2011.09.010.

  15. Kahl BS, Dreyling M, Gordon LI, Quintanilla-Martinez L, Sotomayor EM. Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop. Leuk Lymphoma 2017;58(7):1561-9. doi: 10.1080/10428194.2017.1283036.

  16. Crowther-Swanepoel D, Houlston RS. Genetic variation and risk of chronic lymphocytic leukaemia. Semin Cancer Biol 2010;20(6):363-9. doi: 10.1016/j.semcancer. 2010.08.006.

  17. Ruiz-Argüelles GJ. Advances in the diagnosis and treatment of acute and chronic leukemia in Mexico. Salud Publica Mex 2016;58(2):291-5. http://dx.doi.org/10.21149/spm. v58i2.7799

  18. Horner M, Ries L, Krapcho M, Neyman N, Aminou R, Howlader, N Altekruse S, et al. SEER Cancer Statistics Review, 1975-2006, National Cancer Institute. Bethesda, MD. 2009.

  19. Rai KR, Jain P. Chronic lymphocytic leukemia (CLL)-Then and now. Am J Hematol 2016;91(3):330-40. doi: 10.1002/ ajh.24282.

  20. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 Jun 15;111(12):5446- 56. doi: 10.1182/blood-2007-06-093906.

  21. Ailawadhi S , Frank R, Advani P, Swaika A,Temkit M, Menghani R, Sharma M, et al. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. Cancer Medicine 2017;6(12):2876-2885. doi: 10.1002/cam4.1246.

  22. Varga G, Mikala G, Andrikovics H, Masszi T. How long does a myeloma patient currently wait for the diagnosis in Hungary? Orv Hetil 2014;155(39):1538-1543. doi: 10.1556/ OH.2014.30000.

  23. Jacob LA, Suresh Babu MC, Lakshmaiah KC, Babu KG, Lokanatha D, Rajeev LK, et al. Multiple myeloma: Experience of an institute in limited resource setting. Indian J Cancer 2017;54(1):340-2. DOI: 10.4103/ijc.IJC_87_17

  24. Oyajobi BO. Multiple myeloma/hypercalcemia. Arthritis Res Ther 2007;9(Suppl.1):1-6. doi: 10.1186/ar2168

  25. Rafae A, Malik MN, Zar MA, Durer S, Durer C. An overview of light chain multiple myeloma: Clinical characteristics and rarities, management strategies, and disease monitoring methods. Cureus 2018;10(8):1-13. doi: 10.7759/ cureus.3148

  26. Goldschmidt N, Zamir L, Poperno A, Kahan NR, Paltiel O. Presenting signs of multiple myeloma and the effect of diagnostic delay on the prognosis. J Am Board Fam Med [Internet] 2016;29(6):702-9. DOI: 10.3122/jabfm. 2016.06.150393.




2020     |     www.medigraphic.com